Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients with Heart Failure

This randomized, double-blind, multicenter study evaluated a single transendocardial administration procedure of mesenchymal precursor cellss or sham-control in 565 intention-to-treat patients with heart failure with reduced ejection fraction on guideline-directed therapies.